Home/Pipeline/VT-5006

VT-5006

Parkinson's Disease

Pre-clinicalActive

Key Facts

Indication

Parkinson's Disease

Phase

Pre-clinical

Status

Active

Company

Vertero Therapeutics

About Vertero Therapeutics

Vertero Therapeutics is an early-stage biotech pioneering an unorthodox, gut-brain axis approach to treating neurodegenerative diseases like Parkinson's. Its lead candidate, VT-5006, is a pre-clinical oral therapeutic designed to modulate a peripheral target in the gut to address protein aggregation and inflammation driving brain pathology. The company is led by a seasoned team with deep drug discovery and development experience and is privately funded, positioning it to advance its novel pipeline.

View full company profile

Therapeutic Areas

Neurodegenerative Diseases Parkinson's Disease

Other Parkinson's Disease Drugs

Drug	Company	Phase	Status
NPT200-11	Neuropore Therapies	Phase 1	Partnered (UCB Pharma), status unclear
NUZ-001	Neurizon Therapeutics	Preclinical	Active
VXX-301	Vaxxinity	Preclinical	Pipeline
BAN2802	BioArctic	Phase 1	Active
CNM-Au8	Clene	Phase 2	Active
hpSC-Derived Neural/Dopaminergic Cells	International Stem Cell	Preclinical/Early Clinical	Inferred Active
SLS-004	Seelos Therapeutics	Preclinical	Research
SLS-007	Seelos Therapeutics	Preclinical	Research
Parkinson's Disease Portfolio (Platform-derived)	WD Pharmaceutical	Not Disclosed (Likely Preclinical/Early Clinical)	Active
UX-DA001	UniXell	Phase 1	Active, with trials ongoing in China and FDA IND cleared in U.S. (as of April 2025)
Parkinson's Disease Research	ProgenaBiome	Research	Active
A9 Dopaminergic Neuron Therapy	Trailhead Biosystems	Pre-clinical	Active